A follow‐up study on 6‐[18F]fluoro‐L‐dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen
Identifieur interne : 001143 ( Istex/Corpus ); précédent : 001142; suivant : 001144A follow‐up study on 6‐[18F]fluoro‐L‐dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen
Auteurs : Anna Brück ; Sargo Aalto ; Elina Rauhala ; Jörgen Bergman ; Reijo Marttila ; Juha O. RinneSource :
- Movement Disorders [ 0885-3185 ] ; 2009-05-15.
English descriptors
- KwdEn :
Abstract
Sixteen subjects with de novo Parkinson's disease (PD) underwent three 6‐[18F]fluoro‐L‐dopa (Fdopa) positron emission tomography (PET) scans during a follow‐up time of 5 years (mean ± SD 5.5 ± 0.4 years) to study the progression of striatal dopaminergic hypofunction. Throughout the study, the smallest Fdopa uptake values were found in the dorso‐caudal part of the putamen contralateral to the side with dominant motor symptoms. The rate of decline in Fdopa uptake in the contralateral putamen was faster in the beginning of the disease and slowed down as the disease progressed. The annual decline in Fdopa influx constant (Ki, unit × 10−3 min−1) was on average 0.5 during the first 2 years and 0.2 during the subsequent 3 years (P = 0.002) in the contralateral putamen. In caudate, the rate of decline in Fdopa values was slower than in the putamen and did not change significantly during the follow‐up time, annual decline in the contralateral caudate being 0.1 between baseline and 2 years and 0.3 between 2 and 5 years (P = 0.4). These results suggest that progression of putaminal dopaminergic hypofuncion in PD follows a nonlinear pattern at least in the contralateral side being faster in the beginning of the disease. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22484
Links to Exploration step
ISTEX:12548E91311719D3CCC6D5C8F6C6C3FA73C373D5Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A follow‐up study on 6‐[18F]fluoro‐L‐dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen</title><author><name sortKey="Bruck, Anna" sort="Bruck, Anna" uniqKey="Bruck A" first="Anna" last="Brück">Anna Brück</name><affiliation><mods:affiliation>Turku PET Centre, University of Turku, Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Aalto, Sargo" sort="Aalto, Sargo" uniqKey="Aalto S" first="Sargo" last="Aalto">Sargo Aalto</name><affiliation><mods:affiliation>Turku PET Centre, University of Turku, Turku, Finland</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Psychology, Åbo Akademi University, Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Rauhala, Elina" sort="Rauhala, Elina" uniqKey="Rauhala E" first="Elina" last="Rauhala">Elina Rauhala</name><affiliation><mods:affiliation>Turku PET Centre, University of Turku, Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Bergman, Jorgen" sort="Bergman, Jorgen" uniqKey="Bergman J" first="Jörgen" last="Bergman">Jörgen Bergman</name><affiliation><mods:affiliation>Turku PET Centre, University of Turku, Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Marttila, Reijo" sort="Marttila, Reijo" uniqKey="Marttila R" first="Reijo" last="Marttila">Reijo Marttila</name><affiliation><mods:affiliation>Department of Neurology, Turku University Hospital, Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Rinne, Juha O" sort="Rinne, Juha O" uniqKey="Rinne J" first="Juha O." last="Rinne">Juha O. Rinne</name><affiliation><mods:affiliation>Turku PET Centre, University of Turku, Turku, Finland</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:12548E91311719D3CCC6D5C8F6C6C3FA73C373D5</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22484</idno><idno type="url">https://api.istex.fr/document/12548E91311719D3CCC6D5C8F6C6C3FA73C373D5/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001143</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A follow‐up study on 6‐[18F]fluoro‐L‐dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen</title><author><name sortKey="Bruck, Anna" sort="Bruck, Anna" uniqKey="Bruck A" first="Anna" last="Brück">Anna Brück</name><affiliation><mods:affiliation>Turku PET Centre, University of Turku, Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Aalto, Sargo" sort="Aalto, Sargo" uniqKey="Aalto S" first="Sargo" last="Aalto">Sargo Aalto</name><affiliation><mods:affiliation>Turku PET Centre, University of Turku, Turku, Finland</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Psychology, Åbo Akademi University, Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Rauhala, Elina" sort="Rauhala, Elina" uniqKey="Rauhala E" first="Elina" last="Rauhala">Elina Rauhala</name><affiliation><mods:affiliation>Turku PET Centre, University of Turku, Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Bergman, Jorgen" sort="Bergman, Jorgen" uniqKey="Bergman J" first="Jörgen" last="Bergman">Jörgen Bergman</name><affiliation><mods:affiliation>Turku PET Centre, University of Turku, Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Marttila, Reijo" sort="Marttila, Reijo" uniqKey="Marttila R" first="Reijo" last="Marttila">Reijo Marttila</name><affiliation><mods:affiliation>Department of Neurology, Turku University Hospital, Turku, Finland</mods:affiliation></affiliation></author><author><name sortKey="Rinne, Juha O" sort="Rinne, Juha O" uniqKey="Rinne J" first="Juha O." last="Rinne">Juha O. Rinne</name><affiliation><mods:affiliation>Turku PET Centre, University of Turku, Turku, Finland</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-05-15">2009-05-15</date><biblScope unit="vol">24</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="1009">1009</biblScope><biblScope unit="page" to="1015">1015</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">12548E91311719D3CCC6D5C8F6C6C3FA73C373D5</idno><idno type="DOI">10.1002/mds.22484</idno><idno type="ArticleID">MDS22484</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>6‐[18F]fluoro‐L‐dopa</term><term>PET</term><term>Parkinson's disease</term><term>progression</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Sixteen subjects with de novo Parkinson's disease (PD) underwent three 6‐[18F]fluoro‐L‐dopa (Fdopa) positron emission tomography (PET) scans during a follow‐up time of 5 years (mean ± SD 5.5 ± 0.4 years) to study the progression of striatal dopaminergic hypofunction. Throughout the study, the smallest Fdopa uptake values were found in the dorso‐caudal part of the putamen contralateral to the side with dominant motor symptoms. The rate of decline in Fdopa uptake in the contralateral putamen was faster in the beginning of the disease and slowed down as the disease progressed. The annual decline in Fdopa influx constant (Ki, unit × 10−3 min−1) was on average 0.5 during the first 2 years and 0.2 during the subsequent 3 years (P = 0.002) in the contralateral putamen. In caudate, the rate of decline in Fdopa values was slower than in the putamen and did not change significantly during the follow‐up time, annual decline in the contralateral caudate being 0.1 between baseline and 2 years and 0.3 between 2 and 5 years (P = 0.4). These results suggest that progression of putaminal dopaminergic hypofuncion in PD follows a nonlinear pattern at least in the contralateral side being faster in the beginning of the disease. © 2009 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Anna Brück MD, PhD</name><affiliations><json:string>Turku PET Centre, University of Turku, Turku, Finland</json:string></affiliations></json:item><json:item><name>Sargo Aalto MSc</name><affiliations><json:string>Turku PET Centre, University of Turku, Turku, Finland</json:string><json:string>Department of Psychology, Åbo Akademi University, Turku, Finland</json:string></affiliations></json:item><json:item><name>Elina Rauhala MD, PhD</name><affiliations><json:string>Turku PET Centre, University of Turku, Turku, Finland</json:string></affiliations></json:item><json:item><name>Jörgen Bergman PhD</name><affiliations><json:string>Turku PET Centre, University of Turku, Turku, Finland</json:string></affiliations></json:item><json:item><name>Reijo Marttila MD, PhD</name><affiliations><json:string>Department of Neurology, Turku University Hospital, Turku, Finland</json:string></affiliations></json:item><json:item><name>Juha O. Rinne MD, PhD</name><affiliations><json:string>Turku PET Centre, University of Turku, Turku, Finland</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>PET</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>6‐[18F]fluoro‐L‐dopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>progression</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Sixteen subjects with de novo Parkinson's disease (PD) underwent three 6‐[18F]fluoro‐L‐dopa (Fdopa) positron emission tomography (PET) scans during a follow‐up time of 5 years (mean ± SD 5.5 ± 0.4 years) to study the progression of striatal dopaminergic hypofunction. Throughout the study, the smallest Fdopa uptake values were found in the dorso‐caudal part of the putamen contralateral to the side with dominant motor symptoms. The rate of decline in Fdopa uptake in the contralateral putamen was faster in the beginning of the disease and slowed down as the disease progressed. The annual decline in Fdopa influx constant (Ki, unit × 10−3 min−1) was on average 0.5 during the first 2 years and 0.2 during the subsequent 3 years (P = 0.002) in the contralateral putamen. In caudate, the rate of decline in Fdopa values was slower than in the putamen and did not change significantly during the follow‐up time, annual decline in the contralateral caudate being 0.1 between baseline and 2 years and 0.3 between 2 and 5 years (P = 0.4). These results suggest that progression of putaminal dopaminergic hypofuncion in PD follows a nonlinear pattern at least in the contralateral side being faster in the beginning of the disease. © 2009 Movement Disorder Society</abstract><qualityIndicators><score>6.572</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1260</abstractCharCount><pdfWordCount>4100</pdfWordCount><pdfCharCount>24054</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>206</abstractWordCount></qualityIndicators><title>A follow‐up study on 6‐[18F]fluoro‐L‐dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen</title><genre><json:string>Serial article</json:string></genre><host><volume>24</volume><pages><total>7</total><last>1015</last><first>1009</first></pages><issn><json:string>0885-3185</json:string></issn><issue>7</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1002/mds.22484</json:string></doi><id>12548E91311719D3CCC6D5C8F6C6C3FA73C373D5</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/12548E91311719D3CCC6D5C8F6C6C3FA73C373D5/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/12548E91311719D3CCC6D5C8F6C6C3FA73C373D5/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/12548E91311719D3CCC6D5C8F6C6C3FA73C373D5/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">A follow‐up study on 6‐[18F]fluoro‐L‐dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2009</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: No conflicts of interest.</note><note>Emil Aaltonen Foundation</note><note>Finnish Parkinson Foundation</note><note>Finnish Neurological Foundation</note><note>Duodecim Foundation</note><note>Clinical Grants (EVO) of Turku University Hospital</note><note>Varsinais‐Suomi Regional Fund</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">A follow‐up study on 6‐[18F]fluoro‐L‐dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen</title><author><persName><forename type="first">Anna</forename><surname>Brück</surname><roleName type="degree">MD, PhD</roleName></persName><note type="correspondence"><p>Correspondence: Turku PET Centre, University of Turku, POB 52, FIN‐20521, Turku, Finland===</p></note><affiliation>Turku PET Centre, University of Turku, Turku, Finland</affiliation></author><author><persName><forename type="first">Sargo</forename><surname>Aalto</surname><roleName type="degree">MSc</roleName></persName><affiliation>Turku PET Centre, University of Turku, Turku, Finland</affiliation><affiliation>Department of Psychology, Åbo Akademi University, Turku, Finland</affiliation></author><author><persName><forename type="first">Elina</forename><surname>Rauhala</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Turku PET Centre, University of Turku, Turku, Finland</affiliation></author><author><persName><forename type="first">Jörgen</forename><surname>Bergman</surname><roleName type="degree">PhD</roleName></persName><affiliation>Turku PET Centre, University of Turku, Turku, Finland</affiliation></author><author><persName><forename type="first">Reijo</forename><surname>Marttila</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Department of Neurology, Turku University Hospital, Turku, Finland</affiliation></author><author><persName><forename type="first">Juha O.</forename><surname>Rinne</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Turku PET Centre, University of Turku, Turku, Finland</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-05-15"></date><biblScope unit="vol">24</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="1009">1009</biblScope><biblScope unit="page" to="1015">1015</biblScope></imprint></monogr><idno type="istex">12548E91311719D3CCC6D5C8F6C6C3FA73C373D5</idno><idno type="DOI">10.1002/mds.22484</idno><idno type="ArticleID">MDS22484</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Sixteen subjects with de novo Parkinson's disease (PD) underwent three 6‐[18F]fluoro‐L‐dopa (Fdopa) positron emission tomography (PET) scans during a follow‐up time of 5 years (mean ± SD 5.5 ± 0.4 years) to study the progression of striatal dopaminergic hypofunction. Throughout the study, the smallest Fdopa uptake values were found in the dorso‐caudal part of the putamen contralateral to the side with dominant motor symptoms. The rate of decline in Fdopa uptake in the contralateral putamen was faster in the beginning of the disease and slowed down as the disease progressed. The annual decline in Fdopa influx constant (Ki, unit × 10−3 min−1) was on average 0.5 during the first 2 years and 0.2 during the subsequent 3 years (P = 0.002) in the contralateral putamen. In caudate, the rate of decline in Fdopa values was slower than in the putamen and did not change significantly during the follow‐up time, annual decline in the contralateral caudate being 0.1 between baseline and 2 years and 0.3 between 2 and 5 years (P = 0.4). These results suggest that progression of putaminal dopaminergic hypofuncion in PD follows a nonlinear pattern at least in the contralateral side being faster in the beginning of the disease. © 2009 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>PET</term></item><item><term>6‐[18F]fluoro‐L‐dopa</term></item><item><term>progression</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-08-12">Received</change><change when="2009-01-15">Registration</change><change when="2009-05-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/12548E91311719D3CCC6D5C8F6C6C3FA73C373D5/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="70"><doi origin="wiley" registered="yes">10.1002/mds.v24:7</doi><numberingGroup><numbering type="journalVolume" number="24">24</numbering><numbering type="journalIssue">7</numbering></numberingGroup><coverDate startDate="2009-05-15">15 May 2009</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="8" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22484</doi><idGroup><id type="unit" value="MDS22484"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2009 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2008-08-12"></event><event type="manuscriptRevised" date="2009-01-09"></event><event type="manuscriptAccepted" date="2009-01-15"></event><event type="firstOnline" date="2009-03-03"></event><event type="publishedOnlineFinalForm" date="2009-05-28"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2009-03-03"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.3.3 mode:FullText" date="2014-07-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.3.3 mode:FullText" date="2014-07-24"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1009</numbering><numbering type="pageLast">1015</numbering></numberingGroup><correspondenceTo>Turku PET Centre, University of Turku, POB 52, FIN‐20521, Turku, Finland===</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22484.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="25"></count><count type="wordTotal" number="5153"></count></countGroup><titleGroup><title type="main" xml:lang="en">A follow‐up study on 6‐[<sup>18</sup>F]fluoro‐L‐dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen<link href="#fn3"></link></title><title type="short" xml:lang="en">Striatal Fdopa Uptake in Parkinson's Disease</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Anna</givenNames><familyName>Brück</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>anna.bruck@utu.fi</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Sargo</givenNames><familyName>Aalto</familyName><degrees>MSc</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Elina</givenNames><familyName>Rauhala</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Jörgen</givenNames><familyName>Bergman</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Reijo</givenNames><familyName>Marttila</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Juha O.</givenNames><familyName>Rinne</familyName><degrees>MD, PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FI" type="organization"><unparsedAffiliation>Turku PET Centre, University of Turku, Turku, Finland</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FI" type="organization"><unparsedAffiliation>Department of Psychology, Åbo Akademi University, Turku, Finland</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="FI" type="organization"><unparsedAffiliation>Department of Neurology, Turku University Hospital, Turku, Finland</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">PET</keyword><keyword xml:id="kwd3">6‐[<sup>18</sup>F]fluoro‐L‐dopa</keyword><keyword xml:id="kwd4">progression</keyword></keywordGroup><fundingInfo><fundingAgency>Emil Aaltonen Foundation</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Finnish Parkinson Foundation</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Finnish Neurological Foundation</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Duodecim Foundation</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Clinical Grants (EVO) of Turku University Hospital</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Varsinais‐Suomi Regional Fund</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Sixteen subjects with de novo Parkinson's disease (PD) underwent three 6‐[18F]fluoro‐L‐dopa (Fdopa) positron emission tomography (PET) scans during a follow‐up time of 5 years (mean ± SD 5.5 ± 0.4 years) to study the progression of striatal dopaminergic hypofunction. Throughout the study, the smallest Fdopa uptake values were found in the dorso‐caudal part of the putamen contralateral to the side with dominant motor symptoms. The rate of decline in Fdopa uptake in the contralateral putamen was faster in the beginning of the disease and slowed down as the disease progressed. The annual decline in Fdopa influx constant (Ki, unit × 10<sup>−3</sup> min<sup>−1</sup>) was on average 0.5 during the first 2 years and 0.2 during the subsequent 3 years (<i>P</i> = 0.002) in the contralateral putamen. In caudate, the rate of decline in Fdopa values was slower than in the putamen and did not change significantly during the follow‐up time, annual decline in the contralateral caudate being 0.1 between baseline and 2 years and 0.3 between 2 and 5 years (<i>P</i> = 0.4). These results suggest that progression of putaminal dopaminergic hypofuncion in PD follows a nonlinear pattern at least in the contralateral side being faster in the beginning of the disease. © 2009 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn3"><p>Potential conflict of interest: No conflicts of interest.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>A follow‐up study on 6‐[18F]fluoro‐L‐dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Striatal Fdopa Uptake in Parkinson's Disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>A follow‐up study on 6‐[</title></titleInfo><name type="personal"><namePart type="given">Anna</namePart><namePart type="family">Brück</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Turku PET Centre, University of Turku, Turku, Finland</affiliation><description>Correspondence: Turku PET Centre, University of Turku, POB 52, FIN‐20521, Turku, Finland===</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sargo</namePart><namePart type="family">Aalto</namePart><namePart type="termsOfAddress">MSc</namePart><affiliation>Turku PET Centre, University of Turku, Turku, Finland</affiliation><affiliation>Department of Psychology, Åbo Akademi University, Turku, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Elina</namePart><namePart type="family">Rauhala</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Turku PET Centre, University of Turku, Turku, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jörgen</namePart><namePart type="family">Bergman</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Turku PET Centre, University of Turku, Turku, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Reijo</namePart><namePart type="family">Marttila</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Turku University Hospital, Turku, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Juha O.</namePart><namePart type="family">Rinne</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Turku PET Centre, University of Turku, Turku, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2009-05-15</dateIssued><dateCaptured encoding="w3cdtf">2008-08-12</dateCaptured><dateValid encoding="w3cdtf">2009-01-15</dateValid><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="tables">1</extent><extent unit="references">25</extent><extent unit="words">5153</extent></physicalDescription><abstract lang="en">Sixteen subjects with de novo Parkinson's disease (PD) underwent three 6‐[18F]fluoro‐L‐dopa (Fdopa) positron emission tomography (PET) scans during a follow‐up time of 5 years (mean ± SD 5.5 ± 0.4 years) to study the progression of striatal dopaminergic hypofunction. Throughout the study, the smallest Fdopa uptake values were found in the dorso‐caudal part of the putamen contralateral to the side with dominant motor symptoms. The rate of decline in Fdopa uptake in the contralateral putamen was faster in the beginning of the disease and slowed down as the disease progressed. The annual decline in Fdopa influx constant (Ki, unit × 10−3 min−1) was on average 0.5 during the first 2 years and 0.2 during the subsequent 3 years (P = 0.002) in the contralateral putamen. In caudate, the rate of decline in Fdopa values was slower than in the putamen and did not change significantly during the follow‐up time, annual decline in the contralateral caudate being 0.1 between baseline and 2 years and 0.3 between 2 and 5 years (P = 0.4). These results suggest that progression of putaminal dopaminergic hypofuncion in PD follows a nonlinear pattern at least in the contralateral side being faster in the beginning of the disease. © 2009 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: No conflicts of interest.</note><note type="funding">Emil Aaltonen Foundation</note><note type="funding">Finnish Parkinson Foundation</note><note type="funding">Finnish Neurological Foundation</note><note type="funding">Duodecim Foundation</note><note type="funding">Clinical Grants (EVO) of Turku University Hospital</note><note type="funding">Varsinais‐Suomi Regional Fund</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>PET</topic><topic>6‐[18F]fluoro‐L‐dopa</topic><topic>progression</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>1009</start><end>1015</end><total>7</total></extent></part></relatedItem><identifier type="istex">12548E91311719D3CCC6D5C8F6C6C3FA73C373D5</identifier><identifier type="DOI">10.1002/mds.22484</identifier><identifier type="ArticleID">MDS22484</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2009 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001143 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001143 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:12548E91311719D3CCC6D5C8F6C6C3FA73C373D5
|texte= A follow‐up study on 6‐[18F]fluoro‐L‐dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen
}}
| This area was generated with Dilib version V0.6.23. |  |